Company Product Description Indication Status
Alnylam Pharmaceuticals Inc., of Cambridge, Mass.    Onpattro (patisiran)  RNAi therapeutic  Hereditary transthyretin-mediated amyloidosis  Approved by Brazilian Health Regulatory Agency (ANVISA) 
Kiadis Pharma NV, of Amsterdam Off-the-shelf natural killer cells from universal donors Off-the-shelf natural killer cells from universal donors Acute myeloid leukemia  FDA cleared clinical study by the Ohio State University in relapsed/refractory AML
Puma Biotechnology Inc., of Los Angeles   Nerlynx (neratinib) HER2-targeting therapy Breast cancer FDA approved a supplemental NDA for use in combination with capecitabine for treatment of adults with advanced or metastatic HER2-positive disease who have received 2 or more prior anti-HER2-based regimens in the metastatic setting 
Translate Bio Inc., of Lexington, Mass.   MRT-5005 mRNA therapeutic Cystic fibrosis FDA granted fast track designation 

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments